Загрузка...
HO-1 drives autophagy as a mechanism of resistance against HER2-targeted therapies
PURPOSE: Targeted therapies have resulted in major advances in the treatment of HER2-positive breast cancers. Despite this, up to 70% of patients will develop resistance to treatment within 2 years and new strategies for targeting resistant disease are needed. METHODS: To identify potential resistan...
Сохранить в:
| Опубликовано в: : | Breast Cancer Res Treat |
|---|---|
| Главные авторы: | , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Springer US
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6997276/ https://ncbi.nlm.nih.gov/pubmed/31705351 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-019-05489-1 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|